Consists of diclofenac sodium, linseed oil, menthol, methyl salicylate
What happens if I overdose Diclofenac sodium (Delete GEL)?
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local, or emergency room immediately. Diclofenac sodium (Delete GEL) may be harmful if swallowed.
Proper storage of Diclofenac sodium (Delete GEL):
Store Diclofenac sodium (Delete GEL) at 77 degrees F (25 degrees C) in the sealed pouch. Brief storage between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Throw away any unused patches 3 months after opening the pouch. The pouch is not child-resistant. Keep Diclofenac sodium (Delete GEL) out of the reach of children and away from pets.
Overdose of Diclofenac sodium (Delete GEL) in details
Overdosage will not ordinarily cause acute problems. If Diclofenac sodium (Delete GEL) sodium ophthalmic solution, 0.1% is accidentally ingested, fluids should be taken to dilute the medication.
What should I avoid while taking Diclofenac sodium (Delete GEL)?
Avoid drinking alcohol. It may increase your risk of stomach bleeding.
Avoid taking aspirin or other NSAIDs while you are taking this medicine.
Ask a doctor or pharmacist before using any cold, allergy, or pain medication. Many medicines available over the counter contain aspirin or other medicines similar to Diclofenac sodium (Delete GEL). Taking certain products together can cause you to get too much of this type of medication. Check the label to see if a medicine contains aspirin, ibuprofen, ketoprofen, or naproxen.
Diclofenac sodium (Delete GEL) warnings
Cardiovascular Thrombotic Events
Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI), and stroke, which can be fatal. Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs. The relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar in those with and without known CV disease or risk factors for CV disease. However, patients with known CV disease or risk factors had a higher absolute incidence of excess serious CV thrombotic events, due to their increased baseline rate. Some observational studies found that this increased risk of serious CV thrombotic events began as early as the first weeks of treatment. The increase in CV thrombotic risk has been observed most consistently at higher doses.
To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible. Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur.
There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID, such as Diclofenac sodium (Delete GEL), increases the risk of serious gastrointestinal (GI) events.
Status Post Coronary Artery Bypass Graft (CABG) Surgery
Two large, controlled, clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke. NSAIDs are contraindicated in the setting of CABG.
Post-MI Patients
Observational studies conducted in the Danish National Registry have demonstrated that patients treated with NSAIDs in the post-MI period were at increased risk of reinfarction, CV-related death, and all-cause mortality beginning in the first week of treatment. In this same cohort, the incidence of death in the first year post-MI was 20 per 100 person years in NSAID-treated patients compared to 12 per 100 person years in non-NSAID exposed patients. Although the absolute rate of death declined somewhat after the first year post-MI, the increased relative risk of death in NSAID users persisted over at least the next four years of follow-up.
Avoid the use of Diclofenac sodium (Delete GEL) sodium delayed-release tablets in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If Diclofenac sodium (Delete GEL) sodium delayed-release tablets are used in patients with a recent MI, monitor patients for signs of cardiac ischemia.
Gastrointestinal Bleeding, Ulceration, and Perforation
NSAIDs, including Diclofenac sodium (Delete GEL), cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients, who develop a serious upper GI adverse event on NSAID therapy, is symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occurred in approximately 1% of patients treated for 3 to 6 months, and in about 2% to 4% of patients treated for one year. However, even short-term therapy is not without risk.
Risk Factors for GI Bleeding, Ulceration, and Perforation
Patients with a prior history of peptic ulcer disease and/or GI bleeding who use NSAIDs had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors. Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs);, smoking, use of alcohol, older age, and poor general health status. Most postmarketing reports of fatal GI events occurred in elderly or debilitated patients. Additionally, patients with advanced liver disease and/or coagulopathy are at increased risk for GI bleeding.
Strategies to Minimize the GI Risks in NSAID-Treated Patients
- •
- Use the lowest effective dosage for the shortest possible duration.
- •
- Avoid administration of more than one NSAID at a time.
- •
- Avoid use in patients at higher risk unless benefits are expected to outweigh the increased risk of bleeding. For such patients, as well as those with active GI bleeding, consider alternate therapies other than NSAIDs.
- •
- Remain alert for signs and symptoms of GI ulceration and bleeding during NSAID therapy.
- •
- If a serious GI adverse event is suspected, promptly initiate evaluation and treatment, and discontinue Diclofenac sodium (Delete GEL) sodium delayed-release tablets until a serious GI adverse event is ruled out.
- •
- In the setting of concomitant use of low-dose aspirin for cardiac prophylaxis, monitor patients more closely for evidence of GI bleeding.
Hepatotoxicity
In clinical trials of Diclofenac sodium (Delete GEL)-containing products, meaningful elevations (i.e., more than 3 times the ULN) of AST (SGOT) were observed in about 2% of approximately 5,700 patients at some time during Diclofenac sodium (Delete GEL) treatment (ALT was not measured in all studies).
In a large, open-label, controlled trial of 3,700 patients treated with oral Diclofenac sodium (Delete GEL) sodium for 2 to 6 months, patients were monitored first at 8 weeks and 1,200 patients were monitored again at 24 weeks. Meaningful elevations of ALT and/or AST occurred in about 4% of patients and included marked elevations (greater than 8 times the ULN) in about 1% of the 3,700 patients. In that open-label study, a higher incidence of borderline (less than 3 times the ULN), moderate (3 to 8 times the ULN), and marked (greater than 8 times the ULN) elevations of ALT or AST was observed in patients receiving Diclofenac sodium (Delete GEL) when compared to other NSAIDs. Elevations in transaminases were seen more frequently in patients with osteoarthritis than in those with rheumatoid arthritis.
Almost all meaningful elevations in transaminases were detected before patients became symptomatic. Abnormal tests occurred during the first 2 months of therapy with Diclofenac sodium (Delete GEL) in 42 of the 51 patients in all trials who developed marked transaminase elevations.
In postmarketing reports, cases of drug-induced hepatotoxicity have been reported in the first month, and in some cases, the first 2 months of therapy, but can occur at any time during treatment with Diclofenac sodium (Delete GEL). Postmarketing surveillance has reported cases of severe hepatic reactions, including liver necrosis, jaundice, fulminant hepatitis with and without jaundice, and liver failure. Some of these reported cases resulted in fatalities or liver transplantation.
In a European retrospective population-based, case-controlled study, 10 cases of Diclofenac sodium (Delete GEL) associated drug-induced liver injury with current use compared with non-use of Diclofenac sodium (Delete GEL) were associated with a statistically significant 4-fold adjusted odds ratio of liver injury. In this particular study, based on an overall number of 10 cases of liver injury associated with Diclofenac sodium (Delete GEL), the adjusted odds ratio increased further with female gender, doses of 150 mg or more, and duration of use for more than 90 days.
Physicians should measure transaminases at baseline and periodically in patients receiving long-term therapy with Diclofenac sodium (Delete GEL), because severe hepatotoxicity may develop without a prodrome of distinguishing symptoms. The optimum times for making the first and subsequent transaminase measurements are not known. Based on clinical trial data and postmarketing experiences, transaminases should be monitored within 4 to 8 weeks after initiating treatment with Diclofenac sodium (Delete GEL). However, severe hepatic reactions can occur at any time during treatment with Diclofenac sodium (Delete GEL).
If abnormal liver tests persist or worsen, if clinical signs and/or symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, abdominal pain, diarrhea, dark urine, etc.), Diclofenac sodium (Delete GEL) sodium delayed-release tablets should be discontinued immediately.
Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, diarrhea, pruritus, jaundice, right upper quadrant tenderness, and "flu-like" symptoms). If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), discontinue Diclofenac sodium (Delete GEL) sodium delayed-release tablets immediately, and perform a clinical evaluation of the patient.
To minimize the potential risk for an adverse liver related event in patients treated with Diclofenac sodium (Delete GEL) sodium delayed-release tablets, use the lowest effective dose for the shortest duration possible. Exercise caution when prescribing Diclofenac sodium (Delete GEL) sodium delayed-release tablets with concomitant drugs that are known to be potentially hepatotoxic (e.g., acetaminophen, antibiotics, anti-epileptics).
Hypertension
NSAIDs, including Diclofenac sodium (Delete GEL) sodium delayed-release tablets, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which may contribute to the increased incidence of CV events. Patients taking angiotensin converting enzyme (ACE) inhibitors, thiazides diuretics, or loop diuretics may have impaired response to these therapies when taking NSAIDs.
Monitor blood pressure (BP) during the initiation of NSAID treatment and throughout the course of therapy.
Heart Failure and Edema
The Coxib and traditional NSAID Trialists’ Collaboration meta-analysis of randomized controlled trials demonstrated an approximately 2-fold increase in hospitalization for heart failure in COX-2 selective-treated patients and nonselective NSAID-treated patients compared to placebo-treated patients. In a Danish National Registry study of patients with heart failure, NSAID use increased the risk of MI, hospitalization for heart failure, and death.
Additionally, fluid retention and edema have been observed in some patients treated with NSAIDs. Use of Diclofenac sodium (Delete GEL) may blunt the CV effects of several therapeutic agents used to treat these medical conditions (e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers [ARBs]).
Avoid the use of Diclofenac sodium (Delete GEL) sodium delayed-release tablets in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If Diclofenac sodium (Delete GEL) sodium delayed-release tablets are used in patients with severe heart failure, monitor patients for signs of worsening heart failure.
Renal Toxicity and Hyperkalemia
Renal ToxicityLong-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury.
Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.
No information is available from controlled clinical studies regarding the use of Diclofenac sodium (Delete GEL) sodium delayed-release tablets in patients with advanced renal disease. The renal effects of Diclofenac sodium (Delete GEL) sodium delayed-release tablets may hasten the progression of renal dysfunction in patients with pre-existing renal disease.
Correct volume status in dehydrated or hypovolemic patients prior to initiating Diclofenac sodium (Delete GEL) sodium delayed-release tablets. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use of Diclofenac sodium (Delete GEL) sodium delayed-release tablets. Avoid the use of Diclofenac sodium (Delete GEL) sodium delayed-release tablets in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function. If Diclofenac sodium (Delete GEL) sodium delayed-release tablets are used in patients with advanced renal disease, monitor patients for signs of worsening renal function.
Hyperkalemia
Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.
Anaphylactic Reactions
Diclofenac sodium (Delete GEL) has been associated with anaphylactic reactions in patients with and without known hypersensitivity to Diclofenac sodium (Delete GEL) and in patients with aspirin-sensitive asthma.
Exacerbation of Asthma Related to Aspirin Sensitivity
A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps; severe, potentially fatal bronchospasm; and/or intolerance to aspirin and other NSAIDs. Because cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, Diclofenac sodium (Delete GEL) sodium delayed-release tablets are contraindicated in patients with this form of aspirin sensitivity. When Diclofenac sodium (Delete GEL) sodium delayed-release tablets are used in patients with preexisting asthma (without known aspirin sensitivity), monitor patients for changes in the signs and symptoms of asthma.
Serious Skin Reactions
NSAIDs, including Diclofenac sodium (Delete GEL), can cause serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. These serious events may occur without warning. Inform patients about the signs and symptoms of serious skin reactions and to discontinue the use of Diclofenac sodium (Delete GEL) sodium delayed-release tablets at the first appearance of skin rash or any other sign of hypersensitivity. Diclofenac sodium (Delete GEL) sodium delayed-release tablets are contraindicated in patients with previous serious skin reactions to NSAIDs.
Premature Closure of Fetal Ductus Arteriosus
Diclofenac sodium (Delete GEL) may cause premature closure of the fetal ductus arteriosus. Avoid use of NSAIDs, including Diclofenac sodium (Delete GEL) sodium delayed-release tablets, in pregnant women starting at 30 weeks of gestation (third trimester).
Hematologic Toxicity
Anemia has occurred in NSAID-treated patients. This may be due to occult or gross blood loss, fluid retention, or an incompletely described effect on erythropoiesis. If a patient treated with Diclofenac sodium (Delete GEL) sodium delayed-release tablets, has any signs or symptoms of anemia, monitor hemoglobin or hematocrit.
NSAIDs, including Diclofenac sodium (Delete GEL) sodium delayed-release tablets, may increase the risk of bleeding events. Co-morbid conditions such as coagulation disorders, concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. Monitor these patients for signs of bleeding.
What should I discuss with my healthcare provider before taking Diclofenac sodium (Delete GEL)?
Diclofenac sodium (Delete GEL) can increase your risk of fatal heart attack or stroke, especially if you use it long term or take high doses, or if you have heart disease. Even people without heart disease or risk factors could have a stroke or heart attack while taking Diclofenac sodium (Delete GEL).
Do not use this medicine just before or after heart bypass surgery (coronary artery bypass graft, or CABG).
Diclofenac sodium (Delete GEL) may also cause stomach or intestinal bleeding, which can be fatal. These conditions can occur without warning while you are using Diclofenac sodium (Delete GEL), especially in older adults.
You should not use Diclofenac sodium (Delete GEL) if you are allergic to Diclofenac sodium (Delete GEL), or if you have ever had an asthma attack or severe allergic reaction after taking aspirin or an NSAID.
To make sure Diclofenac sodium (Delete GEL) is safe for you, tell your doctor if you have:
-
heart disease, high blood pressure, high cholesterol, diabetes, or if you smoke;
-
a history of heart attack, stroke, or blood clot;
-
a history of stomach ulcers or bleeding;
-
asthma;
-
liver or kidney disease;
-
fluid retention.
Taking Diclofenac sodium (Delete GEL) during the last 3 months of pregnancy may harm the unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.
It is not known whether Diclofenac sodium (Delete GEL) passes into breast milk or if it could harm a nursing baby. You should not breast-feed while using this medicine.
Diclofenac sodium (Delete GEL) is not approved for use by anyone younger than 18 years old.
Diclofenac sodium (Delete GEL) precautions
General
All topical nonsteroidal anti-inflammatory drugs (NSAIDs) may slow or delay healing.
Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.
Use of topical NSAIDs may result in keratitis. In some susceptible patients continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal infiltrates, corneal erosion, corneal ulceration, and corneal perforation. These events may be sight-threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs and should be closely monitored for corneal health.
Postmarketing experience with topical NSAIDs suggests that patients experiencing complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface disease (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events, which may become sight-threatening.
Topical NSAIDs should be used with caution in these patients.
Postmarketing experience with topical NSAIDs also suggests that use more than 24 hours prior to surgery or use beyond 14 days postsurgery may increase patient risk for occurrence and severity of corneal adverse events.
It is recommended that Diclofenac sodium (Delete GEL) sodium ophthalmic solution, 0.1%, like other NSAIDs, be used with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time. Use of the same bottle for both eyes is not recommended with topical eye drops that are used in association with surgery.
Results from clinical studies indicate that Diclofenac sodium (Delete GEL) sodium ophthalmic solution, 0.1% has no significant effect upon ocular pressure. However, elevations in intraocular pressure may occur following cataract surgery.
Information for Patients
Except for the use of a bandage hydrogel soft contact lens during the first 3 days following refractive surgery, Diclofenac sodium (Delete GEL) sodium ophthalmic solution, 0.1% should not be used by patients currently wearing soft contact lenses due to adverse events that have occurred in other circumstances.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Long-term carcinogenicity studies in rats given Diclofenac sodium (Delete GEL) sodium ophthalmic solution, 0.1% in oral doses up to 2mg/kg/day (approximately 500 times the human topical ophthalmic dose) revealed no significant increases in tumor incidence. A 2-year carcinogenicity study conducted in mice employing oral Diclofenac sodium (Delete GEL) sodium ophthalmic solution, 0.1% up to 2 mg/kg/day did not reveal any oncogenic potential. Diclofenac sodium (Delete GEL) sodium ophthalmic solution, 0.1% did not show mutagenic potential in various mutagenicity studies including the Ames test. Diclofenac sodium (Delete GEL) sodium ophthalmic solution, 0.1% administered to male and female rats at 4 mg/kg/day (approximately 1000 times the human topical ophthalmic dose) did not affect fertility.
Geriatric Use
No overall differences in safety or effectiveness have been observed between elderly and younger adult patients.
PREGNANCY
Teratogenic Effects
Pregnancy Category C. Reproduction studies performed in mice at oral doses up to 5,000 times (20 mg/kg/day) and in rats and rabbits at oral doses up to 2,500 times (10 mg/kg/day) the human topical dose have revealed no evidence of teratogenicity due to Diclofenac sodium (Delete GEL) sodium ophthalmic solution, 0.1% despite the induction of maternal toxicity and fetal toxicity. In rats, maternally toxic doses were associated with dystocia, prolonged gestation, reduced fetal weights and growth, and reduced fetal survival. Diclofenac sodium (Delete GEL) sodium ophthalmic solution, 0.1% has been shown to cross the placental barrier in mice and rats. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Non-teratogenic Effects
Because of the known effects of prostaglandin biosynthesis inhibiting drugs on the fetal cardiovascular system (closure of ductus arteriosus), the use of Diclofenac sodium (Delete GEL) sodium ophthalmic solution, 0.1% during late pregnancy should be avoided.
Nursing Women
It is not known whether topical ophthalmic administration of Diclofenac sodium (Delete GEL) sodium ophthalmic solution, 0.1% could result in sufficient systemic absorption to produce detectable quantities in breast milk. Because many drugs are excreted in human milk, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Pediatric Use
Safety and effectiveness in pediatric patients have not been established.
What happens if I miss a dose of Diclofenac sodium (Delete GEL)?
Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.
What happens if I overdose Menthol (Delete GEL)?
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local ( ), or emergency room immediately. Menthol (Delete GEL) may be harmful if swallowed.
Proper storage of Menthol (Delete GEL):
Store Menthol (Delete GEL) at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat and direct sunlight. Keep Menthol (Delete GEL) out of the reach of children and away from pets.
Menthol (Delete GEL) warnings
For external use only
Ask a doctor before use if you have
- cough that occurs with too much phlegm (mucus)
- chronic cough that lasts or as occurs with smoking, asthma, or emphysema
When using this product
- do not heat
- do not microwave
- do not add to hot water or any container where heating water. May cause splattering and result in burns.
- do not take by mouth or place in nostrils
- do not get into eyes
Stop use and ask a doctor if
- cough lasts more than 7 days, comes back, or occurs with fever, rash, or headache that lasts. These could be signs of a serious condition.
Keep out of reach of children.
If swallowed, get medical help or contact a Poison Control Center right away.
What should I discuss with my healthcare provider before taking Menthol (Delete GEL)?
Some medical conditions may interact with Menthol (Delete GEL). Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
- if you are pregnant, planning to become pregnant, or are breast-feeding
- if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement
- if you have allergies to medicines, foods, or other substances
- if you have cut, scraped, irritated, or damaged skin at the application site
Some MEDICINES MAY INTERACT with Menthol (Delete GEL). However, no specific interactions with Menthol (Delete GEL) are known at this time.
Ask your health care provider if Menthol (Delete GEL) may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Menthol (Delete GEL) precautions
Avoid direct instillation of Menthol (Delete GEL)-containing preparations into the nostrils of infants and young children. Pregnancy and lactation.
Methyl salicylate (Delete GEL) warnings
Methyl salicylate (Delete GEL) cream should not be used on infants. Keep away from eyes and open wounds. Do not use heat lamps, heat pads or bandages and if a rash or irritation occurs discontinue use and contact your doctor or pharmacist.
What should I discuss with my healthcare provider before taking Methyl salicylate (Delete GEL)?
- If you are allergic to Methyl salicylate (Delete GEL) (methyl salicylate); any part of Methyl salicylate (Delete GEL) (methyl salicylate); or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had.
This medicine may interact with other drugs or health problems.
Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take Methyl salicylate (Delete GEL) (methyl salicylate) with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor.
Methyl salicylate (Delete GEL) precautions
For external use only. In conditions arising from more serious underlying causes, consult a doctor.
References
- DailyMed. "MENTHOL; METHYL SALICYLATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DailyMed. "DICLOFENAC EPOLAMINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DrugBank. "Methyl salicylate". http://www.drugbank.ca/drugs/DB09543 (accessed September 17, 2018).
Reviews
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
